Patients treated in community settings were more likely to be older, less likely to be White, and had worse survival rates, ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...

With positive mid-stage results in marginal zone lymphoma, Bristol Myers Squibb could soon add a new indication for the CAR T ...

ASH 2024 featured practice-changing studies in lymphoid malignancies, including tafasitamab’s impact in FL, ibrutinib’s OS benefit in MCL, and promising epcoritamab data in CLL.

Panelists discuss how therapy sequencing is approached for patients with chronic lymphocytic leukemia (CLL), with a focus on ...

Significant growth trajectory of the Breast Cancer Application segment, which is expected to reach US$374.1 Million by 2030 ...

Introduction Blood cancer diagnostics refers to the process of detecting and identifying cancers that affect the blood, bone marrow, and lympha ...

would result in better progression-free survival than chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia (CLL) is unknown. In this phase 3, open-label trial, we included ...

For 24 years, the Lymphoma, Leukemia & Myeloma Congress has stood as the premier educational conference dedicated to hematologic malignancies. Over 75 experts from around the globe gather in New ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK ...

NEW YORK – Galapagos said on Monday that it has partnered with NecstGen, a contract development and manufacturing organization (CDMO), to support decentralized manufacturing of Galapagos' cell therapy ...

Students from three Greater Cincinnati high schools are teaming up to make a difference in the fight against cancer.